Recent breakthroughs in gene therapy and genome editing technologies highlight a surge in precision medicine approaches. SpliceBio secured a $135 million Series B to advance its FDA-authorized dual AAV gene therapy for Stargardt disease, representing an important step in rare disease treatment. Meanwhile, researchers demonstrated that inducing autophagy significantly enhances homologous recombination efficiency in CRISPR-Cas9 gene editing, potentially overcoming a major technical hurdle. Other studies reveal advances in selective RNA modification and the expansion of gene editing capabilities for multiplex targeting, widening therapeutic possibilities.